Hosted on MSN
Merck's Keytruda gets new FDA approval for expanded use in pretreated ovarian cancer patients
The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s MRK Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel, ...
Merck spent most of a decade trailing the S&P 500, then something unusual happened in a single year that changed the entire ...
Management says the post-Keytruda plan is on track. "Our belief in our ability to have substantial growth once we get closer ...
Week Range: $78 to $157Market Cap: around $367 billionStreet Mean Target: around $154Forward 2-Year Revenue Growth (CAGR): around 4%NTM EV/EBITDA: around 17xLTM Gross Margin: 75. 9%Dividend Yield: 2.
Trodelvy plus Keytruda may maintain QOL and delay physical decline in PD-L1-positive mTNBC patients. The combination therapy showed improved progression-free survival and reduced symptom burden ...
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
Gilead Sciences (NASDAQ:GILD) announced Saturday that its antibody-drug conjugate Trodelvy, in combination with Merck’s (NYSE:MRK) immunotherapy Keytruda, cut the risk of disease progression or death ...
Keytruda and Padcev combination shows improved event-free and overall survival in muscle invasive bladder cancer patients ineligible for cisplatin. The KEYNOTE-905/EV-303 trial demonstrated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results